• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Eosinophilic colitis in children: a new and elusive enemy?
ConclusionThis study focus attention on EC as a new challenging pathology. Multicentric randomized clinical trials are needed to understand physiopathological mechanisms to validate a possible endoscopic score and related histological threshold, and to standardize therapy according to clinical features and instrumental findings. The high prevalence of EC in ASD need further specific research.
Source: Pediatric Surgery International - January 7, 2021 Category: Surgery Source Type: research

Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice
Conclusion In conclusion, the present study showed that the oral administration of L. plantarum KLDS1.0318 normalized the parameters altered by CTX-induced toxicities, strengthening intestinal health by regulating the Th1/Th2 balance, ameliorating the intestinal morphology and improving profiles of intestinal microbiota and metabolism. Therefore, our findings suggested that the administration of L. plantarum KLDS1.0318 could be of significant advantage in reducing intestinal immunity impairment caused by cyclophosphamide. Ethics Statement This study was carried out according to the Animal Care Review Committee, Northeas...
Source: Frontiers in Microbiology - April 11, 2019 Category: Microbiology Source Type: research

Peri-operative, intravenous clindamycin may improve the resolution rate of hypertension after Roux-en-Y gastric bypass in morbidly obese patients
ConclusionProphylactic peri-operative, intravenous clindamycin was associated with significantly increased resolution of post-operative hypertension compared to cefazolin. This finding was not observed in SG patients. Future studies are needed to confirm the mechanism of action for this novel finding is due to the differing modifications of the gastrointestinal microflora after RYGB resulting from the specific peri-operative antibiotic administered.
Source: Surgical Endoscopy - February 7, 2019 Category: Surgery Source Type: research

Diffuse Esophageal Spasm: Corkscrew Esophagus
An 84-year-old man with a 1-year history of progressive dysphagia, regurgitation of food, chest pain, and weight loss presented to our outpatient department. He had no previous cardiovascular or gastrointestinal problems, or history of an allergy. He did not experience ataxia, loss of consciousness, disorientation, or difficulty swallowing. His vital signs were normal. A plain radiograph showed no abnormality. Complete blood examination, including blood chemistry analysis, was unremarkable. Upper gastrointestinal endoscopy revealed circular folds in the distal esophagus (i.e., corkscrew esophagus, Figure 1A).
Source: The American Journal of Medicine - September 21, 2017 Category: General Medicine Authors: Hiroki Matsuura Tags: Clinical Communication to the Editor Source Type: research

Celiac disease: 5 things parents need to know
Dr. Dascha Weir, associate director, Boston Children’s Celiac Disease Program It may be difficult for parents to hear that their child has a chronic illness. When the diagnosis is celiac disease (CD), an autoimmune disorder caused by an intolerance to gluten, there is good news. CD is treatable by changes in diet. How it works: When food enters the stomach, it’s broken down into tiny digestible particles, which then travel through the small intestine. The small intestine is lined with villi — tiny finger-like projections that absorb nutrients from the food passing through. In celiac disease, gluten, which is a pro...
Source: Thrive, Children's Hospital Boston - September 28, 2016 Category: Pediatrics Authors: Maureen McCarthy Tags: Diseases & Conditions celiac disease Dr. Dascha Weir gluten intolerance Source Type: news

Evolution of nonspecific duodenal lymphocytosis over 2 years of follow-up.
CONCLUSION: DL may have a multifactorial origin but the IELs infiltrate and HLA are strong predictive factors for CD development and a clinical diagnosis of GS. PMID: 26140001 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - June 28, 2015 Category: Gastroenterology Authors: Losurdo G, Piscitelli D, Giangaspero A, Principi M, Buffelli F, Giorgio F, Montenegro L, Sorrentino C, Amoruso A, Ierardi E, Di Leo A Tags: World J Gastroenterol Source Type: research

Fewer People Are Sensitive To Gluten Than Commonly Believed
By Julie Upton for U.S. News It seems as if everyone is going to great lengths to avoid gluten, a protein found in wheat, barley, rye and many processed foods. Are there real health benefits associated with going gluten-free, or is it just another passing fad? A recently published study in the journal Digestion found that 86 percent of individuals who believed they were gluten sensitive could tolerate it. Individuals with celiac disease, a hereditary autoimmune condition that affects about 3 million Americans, or roughly 1 percent of the population, must avoid gluten. Those with extremely rare wheat allergies must also r...
Source: Healthy Living - The Huffington Post - June 21, 2015 Category: Consumer Health News Source Type: news

Unremitting abdominal pain: obscure until the first CT
We present a patient with a clinical entity that deserves better recognition, first suspected by its typical imaging findings. The case A healthy elderly patient presented with several months’ history of diffuse abdominal pain of mild to moderate intensity becoming relentless with time with no associated weight loss, fever or anorexia. Examination, X-rays, laboratory tests, gastroscopy and colonoscopy were normal and no diagnosis was reached over several months. On admission, abdominal CT revealed lymphadenopathy (up to 3.0x1.5 cm) and mesenteric fat infiltration suggestive of sclerosing mesenteritis (SCM) (figu...
Source: Postgraduate Medical Journal - April 15, 2014 Category: Journals (General) Authors: Schattner, A., Feldberg, E., Adi, M. Tags: Endoscopy, Immunology (including allergy), Pain (neurology), Colon cancer, Eating disorders, Radiology, Connective tissue disease, Dermatology, Surgical diagnostic tests, Gastrointestinal surgery, General surgery, Epidemiology Images in medicine Source Type: research